
NICE reject Clovis Oncology’s ovarian cancer drug Rubraca
pharmafile | August 6, 2019 | News story | Manufacturing and Production | NHS, NICE, Rubraca, UK, guidance, pharma
Britain’s cost-effectiveness body NICE has chosen not to recommend Clovis Oncology’s cancer drug Rubraca (rucaparib).
On 6 August, NICE issued draft guidance that does not recommend Rubraca for maintenance treatment of relapsed ovarian, fallopian tube or peritoneal cancer that has responded to platinum-based chemotherapy.
While data from clinical trials shows the drug extends the length of time a person’s cancer progresses compared with placebo (median of 10.8 months in the rucaparib group compared with 5.4 months in the placebo group), it is not known how much longer people live due to immature trial data.
However, the cost effectiveness estimates are also higher than the amounts the NHS considers an acceptable use of resources. Furthermore, rucaparib does not meet the criteria for inclusion in the cancer drugs fund.
Louis Goss
Related Content

A community-first future: which pathways will get us there?
In the final Gateway to Local Adoption article of 2025, Visions4Health caught up with Julian …

The Pharma Files: with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust
Pharmafile chats with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust, about …

Is this an Oppenheimer moment for the life sciences industry?
By Sabina Syed, Managing Director at Visions4Health In the history of science, few initiatives demonstrate …






